United States: Sandoz Was Disinvited To The Patent Dance: The Federal Circuit’s First Interpretation Of The BPCIA Will Have To Wait

Since the 1984 enactment of the Drug Price Competition and Patent Term Restoration Act, Hatch-Waxman litigation has dominated the sphere of life-sciences patent litigation. The battle between proprietary and generic interests, which have often intertwined over the last thirty years, has changed the landscape of pharmaceutical small molecules.

And so it is with the Biologics Price Competition and Innovation Act of 2009 ("BPCIA"). Industry observers expect the litigation of biologics and so-called biosimilars to be significant and to reshape the sale of biologics, just as the Hatch-Waxman Act did for small-molecule pharmaceuticals. Thus far, however, every attempt to judicially define the contours of the BPCIA has failed.

On December 5, 2014, the U.S. Court of Appeals for the Federal Circuit issued its first decision on a case involving the BPCIA, upholding the dismissal of a declaratory judgment action that Sandoz, the generic arm of Novartis, filed with respect to two Amgen-licensed patents covering Amgen's blockbuster biologic, Enbrel®. The court of appeals agreed with the district court that there was no case or controversy between the parties. In so doing, the court of appeals expressly declined to hold that a failure to file an FDA approval application necessarily results in lack of declaratory judgment jurisdiction.

Background

In 1998, the FDA granted a Biologics License for etanercept to Amgen's predecessor, Immunex, Inc. Amgen markets etanercept under the tradename Enbrel®. In 2004, Sandoz began developing its own biosimilar entanercept product with the expectation that Amgen's last Enbrel® patent would expire in 2014. Amgen then announced two previously unpublished U.S. patents , issued in 2011 and 2012, which it had licensed from Hoffman-La Roche. Amgen took the position that these patents are "related to Enbrel®," and that they extended patent protection for Enbrel® until 2029.

In 2013, Sandoz initiated a Phase III clinical trial on its entanercept product. Simultaneously, Sandoz filed a declaratory judgment action in the U.S. District Court for the Northern District of California against Amgen and Hoffman-LaRoche (collectively, "Amgen") seeking a judgment of noninfringement, invalidity, and unenforceability. At the time of filing, Sandoz had not filed an application for a biosimilar product under the BPCIA (42 U.S.C. § 262(k)).

At the Federal Circuit, the case was one of first impression. The BPCIA borrows liberally from, but is not identical to, the Hatch-Waxman Act. Its framework is highly structured, requiring the biosimilar applicant to notify the biologic sponsor, engage in a mutual exchange of information, and enter into a mandatory negotiation over a fixed period to define the scope of the litigation. However, in what is effectively a Catch-22, Sandoz could not avail itself of this statutory scheme because it had not yet filed an application under 42 U.S.C. § 262(k).

District Court Action

Sandoz argued that the BPCIA does not provide the exclusive remedy for judicial review of the status of Amgen's patents and that a declaratory judgment action was proper under the Declaratory Judgment Act, 28 U.S.C. § 2201, based on principles set out in MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007). According to Sandoz, the MedImmune test would be satisfied as to either party in a proceeding that the BPCIA governs, where the biosimilar applicant notified the reference product sponsor of commercial marketing no later than 180 days before such marketing. Sandoz so notified Amgen.

Amgen argued that the declaratory judgment action was premature for two separate and distinct reasons. First, it contended that the district court lacked statutory authority to consider a patent dispute involving a biosimilar product until after Sandoz filed an FDA biosimilar application. In essence, Amgen argued that the statutory framework of the BPCIA provides the exclusive remedy for patent disputes involving biosimilar products. Second, Amgen argued that the MedImmune test was not satisfied as no cognizable case or controversy exists between the parties.

In her decision of November 12, 2013, District Judge Maxine M. Chesney dismissed the action, adopting both of the grounds Amgen advanced: i) That the BPCIA provided an exclusive remedy for the claims advanced and here its procedural requirements had not been satisfied; and ii) that Sandoz's intent to file an FDA application in the future was not enough to create a threat of injury concrete and immediate enough to support federal jurisdiction.

Federal Circuit Decision

On December 5, 2014, the Federal Circuit panel affirmed the dismissal, addressing solely the MedImmune test under the Declaratory Judgment Act. In reaching this decision, the court of appeals considered Sandoz's failure to file an FDA biosimilars application to be highly probative of the absence of a "case or controversy," but it stopped short of establishing a bright-line rule that such a filing was an absolute predicate. Instead, the panel focused on the "reality and immediacy" aspects required to establish a case or controversy, reasoning that there were too many contingencies for Sandoz to sustain its action. Perhaps the most significant unknown was that Sandoz's biosimilar was still in Phase III trials, the success of which was far from guaranteed.

The Court expressly refused to rule on the district court's conclusion that the BPCIA framework provided the exclusive basis for a declaratory judgment. The question will remain open until a declaratory judgment plaintiff satisfies the MedImmune test while concurrently not satisfying the prerequisites of the BPCIA. It is not clear whether such a case is possible because there is no clear and apparent path for a plaintiff to establish a case or controversy without a pending FDA application.

On the Horizon

The Federal Circuit may be revisiting these same issues again soon if Celltrion appeals the December 1, 2014 dismissal of its declaratory judgment action in Celltrion Healthcare Co. v. Kennedy Trust for Rheumatology Research, 2014 U.S. Dist. LEXIS 166491 (S.D.N.Y. Dec. 1, 2014). Celltrion brought this action against patent owner Kennedy Trust on patents related to methods for treating rheumatoid arthritis ("RA"). Janssen Biotech, Kennedy's licensee, markets Remicade® for the treatment of RA.

Celltrion began developing Remsina®, its biosimilar of Remicade®, in 2008 and successfully completed its clinical trials. Celltrion competes with Janssen in other countries already and wanted the U.S. courts' guidance as to Celltrion's ability to compete in the U.S. Celltrion submitted its FDA application under § 315(k) of the BPCIA (42 U.S.C. § 262(k)) in November 2013, and completed the application in August 2014. Celltrion expects final approval in the first quarter of 2015. Earlier this year, but before the 315(k) application was complete, Celltrion filed its declaratory judgment action.

Judge Paul A. Crotty of the U.S. District Court for the Southern District of New York dismissed the action, ruling that Celltrion could not establish a case or controversy. Despite Celltrion's significant investment in the development of Remsina® and Celltrion's diligent pursuit of FDA approval, Judge Crotty found "these approval preparations are simply not at a stage that can support a declaratory judgment action" under the MedImmune standard.

Judge Crotty seems to disagree with Judge Chesney as to the exclusivity of the BPCIA dispute resolution framework, as a technical matter:

Even if the Court were to find that Celltrion had [satisfied the requirements to establish a case or controversy], the Court would still exercise its discretion to decline to hear this case in light of the existence of the BPCIA statutory framework for the resolution of patent disputes in the licensing of biosimilars.

Celltrion Healthcare Co., at *12 (emphasis added). Judge Crotty's language, then, suggests that a declaratory judgment action might be a discretionary avenue outside of formal BPCIA procedures.

While a Celltrion appeal could theoretically place the exclusivity issues squarely before the Federal Circuit, the fact that Celltrion's application was not approved at the time of suit may provide the court with a simpler exit. In the meantime, we continue to wait for the first BPCIA case to proceed to the merits.

Footnote

[1] U.S. Patents 8,063,182 and 8,163,522.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.